🚀 VC round data is live in beta, check it out!
Enzymatica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Enzymatica and similar public comparables like FitLife Brands, Biome Australia, Hofseth BioCare, Vita Life Sciences and more.
Enzymatica Overview
About Enzymatica
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
Founded
2007
HQ
Employees
18
Website
Financials (LTM)
EV
$69M
Enzymatica Financials
Enzymatica reported last 12-month revenue of $6M.
Revenue (LTM)
Enzymatica P&L
In the most recent fiscal year, Enzymatica reported revenue of $6M and EBITDA of ($5M).
Enzymatica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (84%) | XXX | XXX | XXX |
| EBIT Margin | (95%) | XXX | (93%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (94%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Enzymatica Stock Performance
Enzymatica has current market cap of $73M, and enterprise value of $69M.
Market Cap Evolution
Enzymatica's stock price is $0.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $69M | $73M | -2.9% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEnzymatica Valuation Multiples
Enzymatica trades at 11.6x EV/Revenue multiple, and (13.8x) EV/EBITDA.
EV / Revenue (LTM)
Enzymatica Financial Valuation Multiples
As of April 18, 2026, Enzymatica has market cap of $73M and EV of $69M.
Equity research analysts estimate Enzymatica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enzymatica has a P/E ratio of (12.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73M | XXX | $73M | XXX | XXX | XXX |
| EV (current) | $69M | XXX | $69M | XXX | XXX | XXX |
| EV/Revenue | 11.6x | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (13.8x) | XXX | XXX | XXX |
| EV/EBIT | (12.1x) | XXX | (12.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 19.3x | XXX | XXX | XXX |
| P/E | — | XXX | (12.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Enzymatica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Enzymatica Margins & Growth Rates
Enzymatica's revenue in the last fiscal year grew by 18%.
Enzymatica's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Enzymatica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (84%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 1% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 50% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 77% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 153% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Enzymatica Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Enzymatica | XXX | XXX | XXX | XXX | XXX | XXX |
| FitLife Brands | XXX | XXX | XXX | XXX | XXX | XXX |
| Biome Australia | XXX | XXX | XXX | XXX | XXX | XXX |
| Hofseth BioCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Vita Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Venture Life Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enzymatica M&A Activity
Enzymatica acquired XXX companies to date.
Last acquisition by Enzymatica was on XXXXXXXX, XXXXX. Enzymatica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Enzymatica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEnzymatica Investment Activity
Enzymatica invested in XXX companies to date.
Enzymatica made its latest investment on XXXXXXXX, XXXXX. Enzymatica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Enzymatica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Enzymatica
| When was Enzymatica founded? | Enzymatica was founded in 2007. |
| Where is Enzymatica headquartered? | Enzymatica is headquartered in Sweden. |
| How many employees does Enzymatica have? | As of today, Enzymatica has over 18 employees. |
| Is Enzymatica publicly listed? | Yes, Enzymatica is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Enzymatica? | Enzymatica trades under ENZY ticker. |
| When did Enzymatica go public? | Enzymatica went public in 2015. |
| Who are competitors of Enzymatica? | Enzymatica main competitors are FitLife Brands, Biome Australia, Hofseth BioCare, Vita Life Sciences. |
| What is the current market cap of Enzymatica? | Enzymatica's current market cap is $73M. |
| What is the current revenue of Enzymatica? | Enzymatica's last 12 months revenue is $6M. |
| What is the current EV/Revenue multiple of Enzymatica? | Current revenue multiple of Enzymatica is 11.6x. |
| Is Enzymatica profitable? | No, Enzymatica is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.